SCHEDULE 13G/A: Adage Capital Management and Principals Disclose 6.68% Passive Stake in Lexeo Therapeutics
Beneficial Ownership Report
Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has disclosed a 6.68% beneficial ownership stake in Lexeo Therapeutics, Inc., holding 2,209,615 shares of common stock as of December 31, 2024.
Summary
- Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Lexeo Therapeutics, Inc.
- The Reporting Persons collectively beneficially own 2,209,615 shares of Lexeo Therapeutics, Inc. Common Stock.
- This ownership represents 6.68% of the total outstanding Common Stock of Lexeo Therapeutics, Inc.
- The percentage is calculated based on 33,065,947 shares of Common Stock outstanding as of November 12, 2024, as reported in the Company's Quarterly Report on Form 10-Q filed on November 13, 2024.
- The shares are held with shared voting power and shared dispositive power by the Reporting Persons.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: Neutral to slightly positive. The filing itself is a factual disclosure of ownership. The presence of a significant stake by a known investment firm like Adage Capital Management could be interpreted as a positive signal by some investors, indicating confidence, but the document itself does not express sentiment.
Positives
- The disclosure indicates a significant investment by Adage Capital Management, L.P., a reputable investment firm, which could be interpreted by the market as a vote of confidence in Lexeo Therapeutics, Inc.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Indicates a significant passive investment by Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross, potentially signaling confidence to other shareholders.
Key Dates
| Date | Description |
|---|---|
| 2024-11-12 | Date of shares outstanding calculation (33,065,947 shares) as reported in the Company's Form 10-Q. |
| 2024-12-31 | Date of event requiring the filing of this statement (beneficial ownership as of year-end). |
| 2025-02-12 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
Lexeo Therapeutics, Adage Capital Management, beneficial ownership, Schedule 13G, common stock, institutional investment, passive stake, healthcare, biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.